GREENWICH TWP., N.J.- A compounding pharmacy with operations in Warren County is working to get essential medicines back inside hospitals.
In September, Quva Pharma announced it had acquired a range of medications from Central Admixture Pharmacy Services (CAPS), a B. Braun subsidiary that has exited the 503B compounding business.
Quva, headquartered in Sugar Land, Texas, has 503B manufacturing facilities in Texas and outside Bloomsbury, New Jersey in Greenwich Township.
A Quva spokesperson told 69 News the transfer of products acquired from CAPS to Quva’s facility in Greenwich Township is underway.
“It is a complex process and we are receiving tremendous support from B.Braun/CAPS and the FDA (Food and Drugs Administration),” the spokesperson said, via email. “We have recruited 36 staff from the CAPS business as part of this process.”
A 503B compounding pharmacy makes large batches of sterile drugs to be sold to healthcare facilities. They’re different from 503A pharmacies, which compound drugs according to prescriptions specific to particular patients.
The exit of CAPS from the 503B business caused concern at the FDA. In early September, prior to Quva’s announcement about acquiring CAPS’ product portfolio, the agency relaxed compounding rules for neonatal starter parenteral nutrition (PN) products, which provide nutrients through an IV to premature and critically ill newborns who cannot receive nutrition by mouth or through a feeding tube.
The FDA said it took action after becoming aware of a potential hospital supply gap of PN brought on by the closure of the CAPS facilities.
CAPS had a pair of 503B compounding pharmacies: one in Phoenix, Arizona, and another in Upper Macungie Township, Lehigh County.
Now, Quva tells 69 News it expects the first supply of compounded medications to go into hospitals in early 2027.
The company’s immediate focus is six neonatal starter TPN formulations (TPN is a specific type of PN), it announced in a news release, as well as four cardioplegia preparations and two Heparin products.
“As part of this transaction, we are also seeking to establish a presence in Allentown where we will undertake some manufacturing as well as warehousing and distribution of our medications,” the Quva spokesperson said, who added that the company is in early-stage discussions with property owners, and so it’s too early to provide a specific location for where those operations would be based.
Copyright 2026 Maranatha Broadcasting Co., Inc.. All Rights Reserved.